Bevacizumab (Avastin)

Description

Bevacizumab (Avastin) is a targeted monoclonal antibody therapy that actively blocks the formation of new blood vessels that tumors need to grow and spread. It works by inhibiting vascular endothelial growth factor (VEGF), a key protein responsible for angiogenesis. By cutting off the tumor’s blood supply, it slows disease progression and supports better treatment outcomes when used alone or alongside chemotherapy.

Doctors prescribe this therapy for the treatment of several types of cancers, including colorectal cancer, non-small cell lung cancer, kidney cancer, cervical cancer, and glioblastoma. Healthcare professionals administer it through intravenous infusion in a clinical setting, ensuring controlled delivery and patient safety. The dosage and frequency depend on the specific cancer type, stage, and the patient’s overall health condition.

This advanced biologic therapy improves treatment precision by specifically targeting cancer-related pathways while limiting damage to healthy tissues. It enhances the effectiveness of other anticancer medicines, making it an important component of combination therapy. Patients often experience better disease control and prolonged survival when they follow a structured treatment plan under medical supervision.

Medical teams closely monitor patients during therapy to detect and manage potential side effects such as high blood pressure, bleeding, proteinuria, or delayed wound healing. Regular check-ups and timely interventions help maintain safety and improve tolerance. Patients should always follow their doctor’s advice regarding treatment schedules and precautions.

This innovative cancer treatment plays a vital role in modern oncology by offering a focused and effective approach to tumor management. Its ability to disrupt tumor blood supply makes it a valuable option for patients seeking advanced and reliable cancer therapy.